{"classes":[{"categories":[{"measurements":[{"comment":"The upper limit for Measure of Dispersion was 'not reached' for this study","groupId":"OG000","lowerLimit":"0.99","upperLimit":"NA","value":"2.88"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Progression-free survival (PFS) is defined as the duration of time from start of treatment to time of progression (20% increase in the sum of the longest diameter of target lesions or a measurable increase in a non-target lesion, or the appearance of new lesions) or death, whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive WEE1 inhibitor MK-1775 PO BID for 5 doses beginning on day 1 and cisplatin IV over 1 hour on day 1.\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nWEE1 Inhibitor AZD1775: Given PO","id":"OG000","title":"Arm I (WEE1 Inhibitor MK-1775, Cisplatin)"},{"description":"Patients receive placebo PO BID for 5 doses beginning on day 1 and cisplatin IV over 2 hour on day 1.\n\nCisplatin: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nPlacebo: Given PO","id":"OG001","title":"Arm II (Placebo, Cisplatin)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time from start of treatment to time of progression or death, whichever occurs first, assessed at 6 months","title":"Progression Free Survival","type":"SECONDARY","unitOfMeasure":"months"}